Cadrenal Therapeutics (CVKD) Return on Capital Employed (2023 - 2026)
Cadrenal Therapeutics (CVKD) posted Return on Capital Employed of 209.03% for Q3 2024, down 50.99% sequentially from 138.45% in Q2 2024, and down 8224.0% YoY from 2.57% in Q4 2023.
Cadrenal Therapeutics (CVKD) Return on Capital Employed (2023 - 2026) Analysis & Trends
Cadrenal Therapeutics has reported Return on Capital Employed for 2 years, with the latest figure at 209.03% in Q3 2024.
- Quarterly Return on Capital Employed fell 8224.0% year-over-year to 209.03% in Q3 2024, while the trailing twelve-month figure through Sep 2024 was 209.03% (down 8224.0% YoY) and the FY2023 annual result came in at 199.72%, changed N/A from the prior year.
- Return on Capital Employed declined to 209.03% in Q3 2024 per CVKD's latest filing, from 138.45% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 74.89% in Q1 2024 and troughed at 302.06% in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 7.88% |
| 10 | Cadrenal Therapeutics | 4.57 Mn | 2.17 Mn | - | -439.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -439.89% |
| Jun 30, 2025 | -197.05% |
| Sep 30, 2024 | -209.03% |
| Jun 30, 2024 | -138.45% |
| Mar 31, 2024 | -74.89% |
| Dec 31, 2023 | -94.37% |
| Sep 30, 2023 | -126.79% |
| Jun 30, 2023 | -199.53% |
| Mar 31, 2023 | -302.06% |